AVSARTAN irbesartan 300 mg film-coated tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avsartan irbesartan 300 mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type b; lactose monohydrate; hypromellose; colloidal anhydrous silica; microcrystalline cellulose; macrogol 6000; magnesium stearate; polysorbate 80 - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

IRBESARTAN/HCT SANDOZ  300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ  300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Irbesartan TIH 75 Ástralía - enska - Department of Health (Therapeutic Goods Administration)

irbesartan tih 75

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; crospovidone; hyprolose; sodium stearylfumarate; lactose monohydrate; titanium dioxide; polyvinyl alcohol; macrogol 3350 - irbesartan tih is indicated for the treatment of hypertension. irbesartan tih is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Irbesartan SPR 75 Ástralía - enska - Department of Health (Therapeutic Goods Administration)

irbesartan spr 75

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; crospovidone; hyprolose; sodium stearylfumarate; lactose monohydrate; titanium dioxide; polyvinyl alcohol; macrogol 3350 - irbesartan spr is indicated for the treatment of hypertension. irbesartan spr is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

AVSARTAN HCT 300/25 irbesartan 300 mg and hydrochlorothiazide 25 mg tablets blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avsartan hct 300/25 irbesartan 300 mg and hydrochlorothiazide 25 mg tablets blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; polysorbate 80; hypromellose; colloidal anhydrous silica; mannitol; sodium starch glycollate type b; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN AND HYDROCHLOROTHIAZIDE tablet Bandaríkin - enska - NLM (National Library of Medicine)

irbesartan and hydrochlorothiazide tablet

west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy

IRBESARTAN AND HYDROCHLOROTHIAZIDE tablet, film coated Bandaríkin - enska - NLM (National Library of Medicine)

irbesartan and hydrochlorothiazide tablet, film coated

hisun pharmaceuticals usa inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving

IRBESARTAN tablet Bandaríkin - enska - NLM (National Library of Medicine)

irbesartan tablet

aurobindo pharma limited - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 75 mg - irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and wi

IRBESARTAN- irbesartan tablet Bandaríkin - enska - NLM (National Library of Medicine)

irbesartan- irbesartan tablet

camber pharmaceuticals, inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 75 mg - irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes an